Daré Bioscience, Inc. Discusses Key Goals with Wall Street Analyzer
August 03, 2017 08:30 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE) discussed with Wall Street Analyzer key goals over the next twenty-four months, including the Ovaprene® clinical...
Daré Bioscience, Inc. announces Memorandum of Understanding with CONRAD for the conduct of the Ovaprene® postcoital test clinical trial
July 24, 2017 08:30 ET
|
Dare Bioscience, Inc.
SAN DIEGO, July 24, 2017 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE) announced today that it has entered into a memorandum of understanding with CONRAD to enter into an agreement in...
Daré Bioscience, Inc. trading on The NASDAQ Capital Market under the symbol “DARE”
July 20, 2017 08:30 ET
|
Dare Bioscience, Inc.
Company focused on the development and commercialization of women’s reproductive health productsDaré to Host Conference Call on Monday, July 24, 2017, at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific...
Daré Bioscience Announces Upcoming Presentation at LD Micro Invitational Conference
June 01, 2017 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, June 01, 2017 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc., a privately-held, clinical-stage healthcare company advancing products for women's reproductive health, today announced that...